• The INFINITI Respiratory Viral Plus is CE Marked.

  • The INFINITI Respiratory Viral Plus is designed to detect 25 common respiratory viruses.

  • The INFINITI Respiratory Viral Plus utilizes the RVP Plus Intellipac, RVP Plus Amp Mix and the RVP Plus BioFilmChip Microarray.

  • The INFINITI Respiratory Viral Plus is automated by the INFINITI Analyzer.

Analytes Detected: 
  • Influenza: A/Swine H1N1 and B

  • Human Parainfluenza Virus (HPIV): 1, 2, 3, 4 

  • Rhinovirus: A and B  

  • Enterovirus: A, B, C, D

  • Coronavirus: HKU1, OC43, NL63, 229E       

  • Human Metapneumovirus (HMPV): A and B  

  • Human Respiratory Syncytial Virus (HRSV): A and B

  • Adenovirus: A, B, C, E

  • Simultaneous multiplexed determination of 25 respiratory viruses including subtypes

  • Rapid turnaround time enhances workflow efficiency

  • Load & Go automated on the INFINITI/INFINITI PLUS Analyzer.

  • Replicate determinations on a single BioFilmChip Microarray ensures quality results

Sample Type and Volume: 
  • Uses nasopharyngeal aspirates (NPA).
  • Requires 4 ul of purified RNA/reaction.
Clinical Relevance: 
  • Respiratory Virus symptoms can vary from annoying colds to life-threatening respiratory failure.
  • Only 28% of hospitalizations and 17% of children with laboratory-confirmed influenza infections were diagnosed as actually having influenza.
Clinical Utility: 
  • Rapid respiratory virus diagnosis of inpatients can lead to benefits in several areas: up to 50% reduction in hospital days, 30% reduction in antibiotic use, and 20% reduction in unnecessary diagnostic tests and procedures.
  • Will allow:
    • public health labs to track multiple viruses with 1 sampling
    • monitoring of viral subtypes in the populace
    • easy integration to existing workflows
  1. K.A. Poehling,, The Underrecognized Burden of Influenza in Young Children NEJM, 2006;355:31-40.
  2. CDC: Disease Surveillance
  3. Hendrickson, K. J.  2005. Cost-effective use of rapid diagnostic
    techniques in the treatment and prevention of viral respiratory infections. Pediatr Ann 34(1) 24-31.